Drugs / Norditropin®FlexProTM
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07553351 Comparator | Jun 2026 → Jul 2028 expected | pituitary deficiency | Kexing Biopharm Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NorditropinFlexProTM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07553351 ↗ |
| Route | Subcutaneous | “Norditropin®FlexProTM 0.035mg/kg/day by subcutaneous injection for 52 weeks” NCT07553351 ↗ |